Isolated left ventricular noncompaction (ILVNC) is a cardiomyopathy that was first described in 1926 as a "spongy myocardium." The disorder results from intrauterine arrest of compaction of the loose interwoven meshwork of the fetal myocardial primordium and subsequent persistence of deep trabecular recesses in the myocardial wall. The classical clinical presentation is a triad of heart failure, arrhythmias, and embolic events from mural thrombi. ILVNC has been associated with several autosomal dominant, X-linked, and mitochondrial genetic mutations that are also shared among other cardiomyopathies. Over the past decade, ILVNC has been subject to intensive research, as it increases the risk for sudden cardiac death. This review focuses on the current understanding of ILVNC in adult populations and attempts to provide organized insight into the disease process, screening, diagnosis, management, role of device therapy, and prognosis. (J Am Coll Cardiol 2015;66:578-85)
Note that if noncompaction is concomitantly present with other structural abnormalities (i.e., hypertrophic cardiomyopathy), the diagnosis of "left ventricular noncompaction in association with" is more appropriate (7) .
ILVNC has gained increasing attention (1,2) because of its association with high rates of mortality and morbidity in adults, including heart failure, thromboembolic events, and tachyarrhythmias (8) . Paradoxically, its prognosis appears better when identified early in childhood (9) . This review focuses on the current understanding of ILVNC in the adult population and provides an illustrative portrayal of the disorder.
EMBRYOLOGY
During embryogenesis, the myocardium consists of a loose network of interwoven fibers separated by deep intertrabecular recesses linking the myocardium with the left ventricular cavity. Between the fifth and eighth weeks of embryonic development, this meshwork compacts, proceeding from the epicardium to the endocardium and from the base of the heart to the apex (3, (10) (11) (12) . Ventricular noncompaction results from intrauterine arrest of this process, due to pressure overload or myocardial ischemia preventing the normal compaction process and regression of the myocardial sinusoids (8) .
Although noncompaction of the myocardium is seen in association with other congenital cardiac abnormalities (Table 1) , it can also occur as a primary disorder in the absence of other structural heart disease (7). This latter circumstance, referred to as ILVNC, is the topic of this review.
PREVALENCE
The true prevalence of ILVNC is difficult to determine because diagnostic criteria are not standardized.
Most studies addressing this issue are from tertiary medical centers and performed in populations with symptoms or abnormal physical examination findings and for family screening of patients with the disorder (8, 9, (13) (14) (15) . Therefore, a major limitation is that available prevalence data are derived from retrospective databases fraught with selection biases. In a report from Switzerland, only 0.014% of patients undergoing echocardiography between January 1984
and December 1998 were identified as ILVNC cases (8) . However, in the past decade, increased awareness of the disorder, as well as improvements in echocardiographic image acquisition and processing, have led to greater detection. Thus, the Swiss study is likely to have underestimated disease prevalence.
ILVNC is significantly more prevalent within the heart failure population (16, 17) , which is not surprising, as heart failure remains its most classical presentation.
GENETICS
ILVNC is a genetically heterogeneous disease that can be either familial or sporadic. Familial recurrence appears more commonly in adults with ILVNC (18) than in children (19) and may be autosomal dominant, X-linked, or mitochondrial in origin. The recurrence of noncompaction phenotypes in families varies between 18% and 50% (8, 20, 21) . Although retrospective designs limit their general applicability, prior studies suggest that a detailed pedigree analysis of patients presenting with ILVNC is warranted. It is also generally recommended that asymptomatic relatives of affected individuals be screened using echocardiography (22) . (26, 27) . In summary, the currently available genetic data suggest significant genetic heterogeneity in ILVNC, and the major genetic cause for familial In a Swiss cohort that was 74% male, reasons for referral included heart failure (62%), abnormal echocardiographic findings (12%), and palpitations (6%) (8) . Presenting symptoms included dyspnea in 79% (65% New York Heart Association [NYHA] functional classes I and II, 35% NYHA functional classes III and IV), chest pain (26%), and atrial fibrillation (26%).
The mean left ventricular ejection fraction was 33%, and 94% of patients had an abnormal electrocardiogram (the most common abnormality was left bundle branch block, observed in w44%). Although embolic events were not a reason for referral in this series, they are a common complication. (60) and irrespective of the degree of left ventricular dysfunction (3, 8) . However, anticoagulation should be approached in these patients with careful weighing of benefit and risk to identify those who will benefit most from this strategy. 
